IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
imdc score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • —0–0
  • —1–2
  • —3–6
Direct Clinical Answer

The IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma calculator is designed for bedside predicting survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification in clinical practice.

Clinical Guidelines & Evidence

Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification

Clinical Indication

The IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma is indicated for bedside clinical practice to support Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Validated across multiple treatment settings including VEGF-targeted therapy and immunotherapy.

Formula & Variables:

Sum of risk factors: Time to therapy <1 year (1 point) + KPS <80% (1 point) + Hemoglobin below normal (1 point) + Calcium above normal (1 point) + Neutrophils above normal (1 point) + Platelets above normal (1 point)

Input Parameters

NameTypeRequiredDescription
time_to_systemic_therapystringYesTime from RCC diagnosis to first-line systemic therapy
karnofsky_performance_statusstringYesKarnofsky Performance Status
hemoglobinstringYesHemoglobin level relative to lower limit of normal
corrected_calciumstringYesCorrected calcium level relative to upper limit of normal
neutrophilsstringYesAbsolute neutrophil count relative to upper limit of normal
plateletsstringYesPlatelet count relative to upper limit of normal

Score Interpretation & Guidance

RangeStageDescription
0–0—0 risk factors
1–2—1-2 risk factors
3–6—3-6 risk factors

Evidence-Based References (EBM)

  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809DOI: 10.1200/JCO.2008.21.4809
  • Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4DOI: 10.1016/S1470-2045(12)70559-4
  • Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126DOI: 10.1056/NEJMoa1712126

Related calculators